{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:02:36Z","timestamp":1775696556502,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40644-018-0168-2","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T11:20:56Z","timestamp":1537442456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-1952","authenticated-orcid":false,"given":"Wolfgang G.","family":"Kunz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf S.","family":"Eschbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp M.","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Auernhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"issue":"5","key":"168_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S2213-8587(17)30401-1","volume":"6","author":"Christoph J Auernhammer","year":"2018","unstructured":"Auernhammer CJ, Spitzweg C, Angele MK, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabet Endocrinol. 2017. \n                    https:\/\/doi.org\/10.1016\/s2213-8587(17)30401-1\n                    \n                  .","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"168_CR2","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372.","journal-title":"J Clin Oncol"},{"key":"168_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","volume":"61","author":"JK Ramage","year":"2012","unstructured":"Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6\u201332.","journal-title":"Gut"},{"key":"168_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105:212\u201344.","journal-title":"Neuroendocrinology"},{"key":"168_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","volume":"34","author":"SM Sadowski","year":"2016","unstructured":"Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-Entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34:588\u201396.","journal-title":"J Clin Oncol"},{"key":"168_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrcardio.2017.47","volume":"14","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski JJ, Anavekar NS, Moynihan TJ, Klarich KW. Pathology, imaging, and treatment of cardiac tumours. Nat Rev Cardiol. 2017;14:536\u201349.","journal-title":"Nat Rev Cardiol"},{"key":"168_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1148\/radiographics.21.2.g01mr15439","volume":"21","author":"C Chiles","year":"2001","unstructured":"Chiles C, Woodard PK, Gutierrez FR, Link KM. Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics. 2001;21:439\u201349.","journal-title":"Radiographics"},{"key":"168_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.109.071712","volume":"51","author":"V Ambrosini","year":"2010","unstructured":"Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET\/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669\u201373.","journal-title":"J Nucl Med"},{"key":"168_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","volume":"252","author":"A Frilling","year":"2010","unstructured":"Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850\u20136.","journal-title":"Ann Surg"},{"key":"168_CR10","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.jacc.2017.01.060","volume":"69","author":"JM Tarkin","year":"2017","unstructured":"Tarkin JM, Joshi FR, Evans NR, et al. Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to [18F]FDG PET imaging. J Am Coll Cardiol. 2017;69:1774\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"168_CR11","volume-title":"Epidemiology: an introduction","author":"KJ Rothman","year":"2012","unstructured":"Rothman KJ. Epidemiology: an introduction. 2nd ed. USA: Oxford University Press; 2012.","edition":"2"},{"key":"168_CR12","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S0735-1097(02)02109-5","volume":"40","author":"UH Pandya","year":"2002","unstructured":"Pandya UH, Pellikka PA, Enriquez-Sarano M, Edwards WD, Schaff HV, Connolly HM. Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients. J Am Coll Cardiol. 2002;40:1328\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"168_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","volume":"87","author":"PA Pellikka","year":"1993","unstructured":"Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188\u201396.","journal-title":"Circulation"},{"key":"168_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/CIRCIMAGING.109.886846","volume":"3","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging. 2010;3:103\u201311.","journal-title":"Circ Cardiovasc Imaging"},{"key":"168_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12020-014-0446-0","volume":"48","author":"J Calissendorff","year":"2015","unstructured":"Calissendorff J, Maret E, Sundin A, Falhammar H. Ileal neuroendocrine tumors and heart: not only valvular consequences. Endocrine. 2015;48:743\u201355.","journal-title":"Endocrine"},{"key":"168_CR16","first-page":"1528","volume":"37","author":"HW Yeung","year":"1996","unstructured":"Yeung HW, Imbriaco M, Zhang JJ, Macapinlac H, Goldsmith SJ, Larson SM. Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide. J Nucl Med. 1996;37:1528\u201330.","journal-title":"J Nucl Med"},{"key":"168_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1055\/s-0030-1267204","volume":"42","author":"H Jann","year":"2010","unstructured":"Jann H, Wertenbruch T, Pape U, et al. A matter of the heart: myocardial metastases in neuroendocrine tumors. Horm Metab Res. 2010;42:967\u201376.","journal-title":"Horm Metab Res"},{"key":"168_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/978-3-642-27994-2_20","volume":"194","author":"C Carreras","year":"2013","unstructured":"Carreras C, Kulkarni HR, Baum RP. Rare metastases detected by (68)Ga-somatostatin receptor PET\/CT in patients with neuroendocrine tumors. Recent Results Cancer Res. 2013;194:379\u201384.","journal-title":"Recent Results Cancer Res"},{"key":"168_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12020-013-0108-7","volume":"47","author":"J Calissendorff","year":"2014","unstructured":"Calissendorff J, Sundin A, Falhammar H. (6)(8)Ga-DOTA-TOC-PET\/CT detects heart metastases from ileal neuroendocrine tumors. Endocrine. 2014;47:169\u201376.","journal-title":"Endocrine"},{"key":"168_CR20","doi-asserted-by":"publisher","first-page":"e112278","DOI":"10.1371\/journal.pone.0112278","volume":"9","author":"W Noordzij","year":"2014","unstructured":"Noordzij W, van Beek AP, Tio RA, et al. Myocardial metastases on 6-[18F] fluoro-L-DOPA PET\/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients. PLoS One. 2014;9:e112278.","journal-title":"PLoS One"},{"key":"168_CR21","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1161\/CIRCULATIONAHA.108.767111","volume":"118","author":"HB Fiebrich","year":"2008","unstructured":"Fiebrich HB, Brouwers AH, Links TP, de Vries EG. Images in cardiovascular medicine: myocardial metastases of carcinoid visualized by 18F-dihydroxy-phenyl-alanine positron emission tomography. Circulation. 2008;118:1602\u20134.","journal-title":"Circulation"},{"key":"168_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0002-9343(64)90145-7","volume":"36","author":"WC Roberts","year":"1964","unstructured":"Roberts WC, Sjoerdsma A. The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med. 1964;36:5\u201334.","journal-title":"Am J Med"},{"key":"168_CR23","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","volume":"69","author":"J Davar","year":"2017","unstructured":"Davar J, Connolly HM, Caplin ME, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: An Expert Statement. J Am Coll Cardiol. 2017;69:1288\u2013304.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-018-0168-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40644-018-0168-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-018-0168-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:13:08Z","timestamp":1568920388000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-018-0168-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1186\/s40644-018-0168-2","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"31 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board of the LMU Munich (Ethikkommission der Medizinischen Fakult\u00e4t der Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen) approved this retrospective study, which was conducted according to the Helsinki Declaration of 2013, and waived requirement for informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"34"}}